Replies to post #381496 on Anavex Life Sciences Corp (AVXL)

[Jonjones325]

The gene pathway poster stated, “These findings will facilitate contextualization of upcoming readout of ANAVEX®2-73 Phase 2b/3 Alzheimer’s disease clinical trial”

“Expression levels of dysregulated neurodegenerative genes were restored by the therapeutic effect of ANAVEX®2-73”

That poster was published July 31st.

I’m guessing at that time they likely had an idea if the Alz trial was successful. Or by looking at the mounds of OLE Alz data from our 2B/3.

Everything the the company has ever said and presented has pointed to the same conclusion. Every piece of 3rd party data has confirmed it as well. Hundreds of patients in the OLEs are also likely adding to their confidence.

Hence no change in language. With the exception of a decrease in qualifiers.

[La Flaca]

While I’m hopeful you’re correct, why do you think that the closer we get to readout at CTAD without a PR signals the unlikelihood that trial failed to meet endpoints? Or is your comment more influenced by the date the trial wrapped up (~ 4 months ago)? Look at CRTX - their PR was issued about 2 weeks before oral presentation at CTAD as a reference and example that they didn’t PR trial failure until 2 weeks before CTAD presentation?

Or is your comment that this, in combination with your other factors, signals that unlikelihood?

[ExtremelyBullishZig]

You forgot the more probable reason. There isn't a delay..they are planning on presenting The TLR and TLD at the conference like they have for the past 7 years. They have only deviated when there wasn't a major conference near...at those times they created their own webinar conference to present.